Burney T L, Badlani G H
Department of Urology, Long Island Jewish Medical Center, New Hyde Park, NY, USA.
J Endourol. 1996 Jun;10(3):273-7. doi: 10.1089/end.1996.10.273.
Management of intrinsic sphincter deficiency (ISD) can be achieved by many techniques. Those patients suffering from urinary incontinence secondary to ISD have often undergone multiple prior procedures for management of incontinence; therefore, an ideal form of treatment would be one that is minimally invasive and safe without compromising efficacy. The bioinjectables have proved to be safe and effective for the management of ISD and offer a minimally invasive alternative that can be performed under local anesthesia. This form of therapy is especially advantageous for properly selected patients suffering from urinary incontinence caused by ISD. We review the properties, indications for use, and results of the bioinjectables used in the treatment of ISD.
内在括约肌缺陷（ISD）的管理可通过多种技术实现。那些因ISD继发尿失禁的患者往往已经接受过多次先前的失禁管理手术；因此，理想的治疗形式应是一种微创且安全同时又不影响疗效的方法。生物注射剂已被证明对ISD的管理是安全有效的，并提供了一种可在局部麻醉下进行的微创替代方法。这种治疗形式对经适当选择的因ISD导致尿失禁的患者特别有利。我们回顾了用于治疗ISD的生物注射剂的特性、使用指征和结果。
